Concentra Biosciences, LLC Sample Contracts
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 29th, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances) • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).
LIMITED GUARANTYLimited Guaranty • July 16th, 2025 • Concentra Biosciences, LLC • Pharmaceutical preparations
This Limited Guaranty, dated as of July 1, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of IGM Biosciences, Inc., a Delaware corporation (the “Company”) and the Representative to be party to the CVR Agreement (as defined below) (the “Representative”). Reference is hereby made to (i) that certain Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”) and the Company, pursuant to which, among other things, Merger Sub will merge with and into the Company with the Company continuing as the surviving corporation in the merger as a wholly owned subsidiary of Parent, on the terms and subject to the conditions set forth in the Merger Agreement and (ii) tha
LIMITED GUARANTYLimited Guaranty • August 1st, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances)
This Limited Guaranty, dated as of July 18, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of iTeos Therapeutics, Inc., a Delaware corporation (the “Company”) and the Representative to be party to the CVR Agreement (as defined below) (the “Representative”). Reference is hereby made to (i) that certain Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”) and the Company, pursuant to which, among other things, Merger Sub will merge with and into the Company with the Company continuing as the surviving corporation in the merger as a wholly owned subsidiary of Parent, on the terms and subject to the conditions set forth in the Merger Agreement and (
Re: Confidentiality AgreementConfidentiality Agreement • July 21st, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances)
As you are aware, CARGO Therapeutics, Inc. (the “Company” or “we”) and Tang Capital Management, LLC and certain of their affiliates (collectively, “you” or “Tang”) desire to enter into discussions regarding a potential business transaction involving the Company (the “Discussions”). In connection with and to facilitate the Discussions, the Company or its representatives (as defined below) may make available to you or your representatives certain non-public information relating to proposed actions by the Board of Directors of the Company and the governance, business, financial condition, operations, initiatives and prospects of the Company and its subsidiaries (the “Confidential Information”). In consideration of being provided that information, you have agreed that you will use the Confidential Information solely for the purpose of the Discussions, and that you will not disclose the Confidential Information to any person in any manner whatsoever prior to August 5, 2025 (the “Termination
Confidentiality AgreementConfidentiality Agreement • July 16th, 2025 • Concentra Biosciences, LLC • Pharmaceutical preparations
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 19th, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances) • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 19, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent (as defined herein), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 14th, 2025 • Concentra Biosciences, LLC • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 14, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company , as Rights Agent (as defined herein), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).
AGREEMENT AND PLAN OF MERGER DATED AS OF JULY 18, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VIII, INC. AND ITEOS THERAPEUTICS, INC.Merger Agreement • August 15th, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER, dated as of July 18, 2025 (this “Agreement” and, such date, the “Agreement Date”), by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and iTeos Therapeutics, Inc., a Delaware corporation (the “Company”).
AGREEMENT FOR DISCLOSURE OF CONFIDENTIAL INFORMATION FROM ITEOS THERAPEUTICS INC.Confidentiality Agreement • August 1st, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances) • Delaware
This Agreement For the Disclosure of Confidential Information from iTeos (“Agreement”) is made as of the 10th day of June, 2025 (“Effective Date”), by and between iTeos Therapeutics Inc., having a place of business at 321 Arsenal St., Watertown, MA 02472 and its Affiliates (collectively hereinafter referred to as “ITEOS“), and Tang Capital Management, LLC having a place of business at 4747 Executive Drive, Suite 210, San Diego, CA 92121 (hereinafter referred to as “Recipient”), each a “Party” and collectively, the “Parties”.
LIMITED GUARANTYLimited Guaranty • July 21st, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances)
This Limited Guaranty, dated as of July 7, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of CARGO Therapeutics, Inc., a Delaware corporation (the “Company”) and the Representative to be party to the CVR Agreement (as defined below) (the “Representative”). Reference is hereby made to (i) that certain Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub VII, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”) and the Company, pursuant to which, among other things, Merger Sub will merge with and into the Company with the Company continuing as the surviving corporation in the merger as a wholly owned subsidiary of Parent, on the terms and subject to the conditions set forth in the Merger Agreement and (ii